Search results for: Innovation Policy Prize
Filter search results
Pharmaceuticals in Developing Countries 1981-82
1 July 1984
Two years ago, the Office of Health Economics published a research paper describing some of the activities of eighteen European pharmaceutical companies in the Developing Countries in ·1979-80 (Worlock 1982)….
Pharmaceuticals in seven nations
1 May 1985
Great Britain at the suggestion of and in close collaboration with Medizinisch Pharmazeutische Studiengesellschaft (MPS) in the Federal Republic of Germany, OHE is funded entirely by the Association of the…
Biosimilar Competition: Lessons from Europe and Prospects for the US
1 October 2014
Based on an OHE lunchtime seminar by Professor Henry Grabowski, this seminar briefing explores the lessons learned from Europe’s experience with biosimilars, and provides an analysis of how the US…
Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
1 March 2015
…Northern Ireland. The report highlights upcoming initiatives that may alter this landscape, describes three promising local programmes that demonstrate opportunities for expanding capabilities, and makes a series of policy recommendations….
International Comparison of Medicines Usage: Quantitative Analysis from a Swedish Perspective
1 May 2015
The OHE undertook an analysis of the uptake of medicines in 13 high income countries. The UK perspective on this was published in November 2014 by the ABPI. OHE has…
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectiveness Evaluations
1 August 2015
Why might the launch price of a new drug be a poor indicator of future expenditure for a drug? Which are the factors that determine the future prices and market…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
1 October 2015
Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. As value is likely to differ across major indications, if prices paid for on-patent…
Dementia: The R&D Landscape
1 November 2015
This OHE Research Paper provides an overview of the current dementia R&D landscape. The research was undertaken by OHE for Imperial College and the UK Department of Health. This OHE…
Data Governance Arrangements for Real-World Evidence
1 November 2015
The objective of this OHE Consulting Report was to understand and develop a view on the core principles that should govern how Real-World Data (RWD) is accessed or generated, and…